醛固酮与血管及代谢功能障碍
Aldosterone in vascular and metabolic dysfunction.
作者信息
Luther James M
机构信息
aDivision of Clinical Pharmacology bDivision of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
出版信息
Curr Opin Nephrol Hypertens. 2016 Jan;25(1):16-21. doi: 10.1097/MNH.0000000000000189.
Abstract
PURPOSE OF REVIEW
This review will highlight recent developments in mineralocorticoid receptor research which impact aldosterone-associated vascular and cardiometabolic dysfunction.
RECENT FINDINGS
The mineralocorticoid receptor is also expressed in vascular smooth muscle and vascular endothelium, and contributes to vascular function and remodeling. Adipocyte-derived leptin stimulates aldosterone secretion, which may explain the observed link between obesity and hyperaldosteronism. Adipocyte mineralocorticoid receptor overexpression produces systemic changes consistent with metabolic syndrome. Ongoing studies with novel nonsteroidal mineralocorticoid receptor antagonists may provide a novel treatment for diabetic nephropathy and heart failure in patients with chronic kidney disease, with reduced risk of hyperkalemia.
SUMMARY
Ongoing research continues to demonstrate novel roles of the vascular and adipocyte mineralocorticoid receptor function, which may explain the beneficial metabolic and vascular benefits of mineralocorticoid receptor antagonists.
摘要
综述目的
本综述将重点介绍盐皮质激素受体研究的最新进展，这些进展影响与醛固酮相关的血管和心脏代谢功能障碍。
最新发现
盐皮质激素受体也在血管平滑肌和血管内皮中表达，并有助于血管功能和重塑。脂肪细胞衍生的瘦素刺激醛固酮分泌，这可能解释了肥胖与醛固酮增多症之间观察到的联系。脂肪细胞盐皮质激素受体过表达会产生与代谢综合征一致的全身变化。正在进行的新型非甾体盐皮质激素受体拮抗剂研究可能为慢性肾脏病患者的糖尿病肾病和心力衰竭提供一种新的治疗方法，同时降低高钾血症风险。
总结
正在进行的研究继续证明血管和脂肪细胞盐皮质激素受体功能的新作用，这可能解释盐皮质激素受体拮抗剂有益的代谢和血管益处。
相似文献
1
Aldosterone in vascular and metabolic dysfunction.醛固酮与血管及代谢功能障碍
Curr Opin Nephrol Hypertens. 2016 Jan;25(1):16-21. doi: 10.1097/MNH.0000000000000189.
2
Vascular actions of aldosterone.醛固酮的血管作用
J Vasc Res. 2013;50(2):89-99. doi: 10.1159/000345243. Epub 2012 Nov 21.
3
Vascular Consequences of Aldosterone Excess and Mineralocorticoid Receptor Antagonism.醛固酮过量与盐皮质激素受体拮抗的血管后果
Curr Hypertens Rev. 2017;13(1):46-56. doi: 10.2174/1573402113666170228151402.
4
Mineralocorticoid Receptor Blockade in End-Stage Renal Disease.终末期肾病的盐皮质激素受体阻断。
Curr Hypertens Rep. 2017 May;19(5):40. doi: 10.1007/s11906-017-0737-y.
5
Aldosterone and inflammation.醛固酮与炎症。
Curr Opin Endocrinol Diabetes Obes. 2010 Jun;17(3):199-204. doi: 10.1097/med.0b013e3283391989.
6
Role of mineralocorticoid receptor and renin-angiotensin-aldosterone system in adipocyte dysfunction and obesity.醛固酮受体和肾素-血管紧张素-醛固酮系统在脂肪细胞功能障碍和肥胖中的作用。
J Steroid Biochem Mol Biol. 2013 Sep;137:99-106. doi: 10.1016/j.jsbmb.2013.02.012. Epub 2013 Feb 28.
7
Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease?醛固酮受体介导的血管胰岛素抵抗：糖尿病相关血管疾病的早期发病因素？
Diabetes. 2013 Feb;62(2):313-9. doi: 10.2337/db12-0905.
8
Aldosterone, mineralocorticoid receptor and the metabolic syndrome: role of the mineralocorticoid receptor antagonists.醛固酮、盐皮质激素受体与代谢综合征：盐皮质激素受体拮抗剂的作用。
Curr Vasc Pharmacol. 2012 Mar;10(2):238-46. doi: 10.2174/157016112799304969.
9
Is there a new dawn for selective mineralocorticoid receptor antagonism?选择性盐皮质激素受体拮抗剂是否迎来了新的曙光？
Curr Opin Nephrol Hypertens. 2014 Sep;23(5):456-61. doi: 10.1097/MNH.0000000000000051.
10
Adipocyte-derived factors regulate vascular smooth muscle cells through mineralocorticoid and glucocorticoid receptors.脂肪细胞衍生因子通过盐皮质激素和糖皮质激素受体调节血管平滑肌细胞。
Hypertension. 2011 Sep;58(3):479-88. doi: 10.1161/HYPERTENSIONAHA.110.168872. Epub 2011 Jul 25.
引用本文的文献
1
Occurrence of Metabolic Disorders in Bilateral Primary Aldosteronism Compared to Unilateral Primary Aldosteronism.双侧原发性醛固酮增多症与单侧原发性醛固酮增多症相比代谢紊乱的发生情况。
Diseases. 2025 Feb 10;13(2):52. doi: 10.3390/diseases13020052.
2
Eight weeks of treatment with mineralocorticoid receptor blockade does not alter vascular function in individuals with and without type 2 diabetes.矿皮质激素受体阻滞剂治疗 8 周不会改变 2 型糖尿病患者和非糖尿病患者的血管功能。
Physiol Rep. 2024 Apr;12(7):e16010. doi: 10.14814/phy2.16010.
3
Atrial fibrillation in heart failure patients: An update on renin-angiotensin-aldosterone system pathway blockade as a therapeutic and prevention target.心力衰竭患者的心房颤动：肾素-血管紧张素-醛固酮系统途径阻断作为治疗和预防靶点的最新进展。
Cardiol J. 2023;30(2):312-326. doi: 10.5603/CJ.a2022.0061. Epub 2022 Jun 28.
4
Comparison of biomarkers of endothelial dysfunction and microvascular endothelial function in patients with primary aldosteronism and essential hypertension.原发性醛固酮增多症与原发性高血压患者内皮功能障碍和微血管内皮功能的生物标志物比较。
J Renin Angiotensin Aldosterone Syst. 2021 Jan-Dec;22(1):1470320321999491. doi: 10.1177/1470320321999491.
5
Biological Pathways in Adolescent Aortic Stiffness.青少年主动脉僵硬度的生物学途径。
J Am Heart Assoc. 2021 Mar 16;10(6):e018419. doi: 10.1161/JAHA.120.018419. Epub 2021 Mar 1.
6
The mineralocorticoid receptor-an emerging player in metabolic syndrome?醛固酮受体——代谢综合征的新角色？
J Hum Hypertens. 2021 Feb;35(2):117-123. doi: 10.1038/s41371-020-00467-3. Epub 2021 Feb 1.
7
Is primary aldosteronism a potential risk factor for aortic dissection? A case report and literature review.原发性醛固酮增多症是否是主动脉夹层的潜在危险因素？一例报告及文献复习。
BMC Endocr Disord. 2020 Jul 31;20(1):115. doi: 10.1186/s12902-020-00601-9.
8
The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure.肾素-血管紧张素-醛固酮系统：从动脉高血压到心力衰竭的十字路口。
Heart Fail Rev. 2020 Jan;25(1):31-42. doi: 10.1007/s10741-019-09855-5.
9
Short- and long-term results of laparoscopic adrenalectomy for Conn's syndrome.腹腔镜肾上腺切除术治疗原发性醛固酮增多症的短期和长期疗效
Wideochir Inne Tech Maloinwazyjne. 2018 Sep;13(3):292-298. doi: 10.5114/wiitm.2018.74833. Epub 2018 Apr 3.
10
Role of Mineralocorticoid Receptors in Obstructive Sleep Apnea and Metabolic Syndrome.醛固酮受体在阻塞性睡眠呼吸暂停和代谢综合征中的作用。
Curr Hypertens Rep. 2018 Mar 19;20(3):23. doi: 10.1007/s11906-018-0819-5.
本文引用的文献
1
Adipocyte-Derived Hormone Leptin Is a Direct Regulator of Aldosterone Secretion, Which Promotes Endothelial Dysfunction and Cardiac Fibrosis.脂肪细胞衍生激素瘦素是醛固酮分泌的直接调节剂，促进内皮功能障碍和心脏纤维化。
Circulation. 2015 Dec 1;132(22):2134-45. doi: 10.1161/CIRCULATIONAHA.115.018226. Epub 2015 Sep 11.
2
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.非奈利酮治疗糖尿病肾病患者蛋白尿的疗效：一项随机临床试验。
JAMA. 2015 Sep 1;314(9):884-94. doi: 10.1001/jama.2015.10081.
3
Nonsteroidal antagonists of the mineralocorticoid receptor.盐皮质激素受体的非甾体拮抗剂。
Curr Opin Nephrol Hypertens. 2015 Sep;24(5):417-24. doi: 10.1097/MNH.0000000000000147.
4
Low-Dose Mineralocorticoid Receptor Blockade Prevents Western Diet-Induced Arterial Stiffening in Female Mice.低剂量盐皮质激素受体阻断可预防西式饮食诱导的雌性小鼠动脉僵硬。
Hypertension. 2015 Jul;66(1):99-107. doi: 10.1161/HYPERTENSIONAHA.115.05674. Epub 2015 May 26.
5
Adipocyte Mineralocorticoid Receptor Activation Leads to Metabolic Syndrome and Induction of Prostaglandin D2 Synthase.脂肪细胞盐皮质激素受体激活导致代谢综合征并诱导前列腺素D2合酶。
Hypertension. 2015 Jul;66(1):149-57. doi: 10.1161/HYPERTENSIONAHA.114.04981. Epub 2015 May 11.
6
Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.ARTS-DN的原理、设计和基线特征：一项评估非奈利酮在2型糖尿病合并糖尿病肾病临床诊断患者中的安全性和有效性的随机研究。
Am J Nephrol. 2014;40(6):572-81. doi: 10.1159/000371497. Epub 2015 Jan 10.
7
Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes.盐皮质激素受体阻断可改善2型糖尿病患者的冠状动脉微血管功能。
Diabetes. 2015 Jan;64(1):236-42. doi: 10.2337/db14-0670. Epub 2014 Aug 14.
8
Is there a new dawn for selective mineralocorticoid receptor antagonism?选择性盐皮质激素受体拮抗剂是否迎来了新的曙光？
Curr Opin Nephrol Hypertens. 2014 Sep;23(5):456-61. doi: 10.1097/MNH.0000000000000051.
9
The associations of adipokines with selected markers of the renin-angiotensinogen-aldosterone system: the multi-ethnic study of atherosclerosis.脂肪因子与肾素-血管紧张素原-醛固酮系统特定标志物的关联：动脉粥样硬化多民族研究
J Hum Hypertens. 2015 Feb;29(2):127-33. doi: 10.1038/jhh.2014.40. Epub 2014 Jun 12.
Zotero 插件